Any other biotech would have put out two separate price sensitive announcements instead of one non-price sensitive titled 'Portfolio Update'.
Anyway, good news, European Commission granting Conditional Marketing Authorisation of HEMGENIX (this in addition to FDA approval) and submission to global health authorities later this calendar year for full approval of garadacimab after successful Phase 3 trial.
This is nice too: "10 products that were potential game changers" in R&D.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |